Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490990 | 1.00 | PDPK1 (0.34) | PDPK1JAK2GPR17DYRK1AIDO1 | |
| SCHEMBL14738326 | 0.81 | MAP2K4 (0.33) | GPR17 | |
| SCHEMBL14737657 | 0.78 | TRPA1 (0.35) | — | |
| SCHEMBL30467571 | 0.78 | PDPK1 (0.34) | PDPK1JAK2DYRK1AIDO1TDO2 | |
| SCHEMBL31162464 | 0.78 | PDPK1 (0.34) | PDPK1JAK2GPR17DYRK1AIDO1 | |
| SCHEMBL24252918 | 0.78 | PDPK1 (0.34) | PDPK1JAK2DYRK1AIDO1TDO2 | |
| SCHEMBL2144129 | 0.78 | PDPK1 (0.34) | PDPK1JAK2GPR17DYRK1AIDO1 | |
| SCHEMBL1317469 | 0.78 | PDPK1 (0.50) | PDPK1JAK2GPR17DYRK1AIDO1 | |
| SCHEMBL31393082 | 0.77 | DYRK1A (0.32) | PDPK1JAK2DYRK1A | |
| SCHEMBL31313054 | 0.77 | JAK1 (0.33) | PDPK1JAK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055363-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024259015-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4221703-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072517-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-113831326-A | Condensed heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2021-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | PDPK1 1978/4885JAK2 3555/4885GPR17 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.